SEC Form 4 · accession 0001140361-15-034271
Raptor Pharmaceutical Corp · RPTP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Raymond Anderson
Director
Period of report
Aug 31, 2015
Accepted (ET)
Sep 2, 2015 · 8:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070698
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 31, 2015 | M | 8,084 | $2.02 | A | 14,779 | D | |
| Common StockF2,F1 | Aug 31, 2015 | S | 8,084 | $12.5176 | D | 6,695 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock options (right to buy)F3 | $2.02 | Aug 31, 2015 | M | 8,084 | D | — | Mar 9, 2020 | Common Stock | 8,084 | 4,916 | D |
Explanation of responses
- F1Includes 5021 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to one (1) share of common stock for each one (1) RSU upon the vesting thereof. The RSUs will vest in full on the first anniversary of the date of grant.
- F2This transaction was executed in multiple trades at prices ranging from $12.50 to $12.63. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3Fully vested and exercisable.